Abstract:The presence of EGFR activating mutations and ALK chromosomic rearrangements with corresponding tyrosine kinase inhibitors (TKIs) has revolutionized the treatment strategies of patients with non-small cell lung cancer (NSCLC). Although tremendously initial response and manageable toxicity profiles, acquired resistance inevitably develops after approximately 1 year treatment with EGFR-TKIs (erlotinib and gefitinib) and ALK inhibitor (crizotinib). Encouragingly, third-generation EGFR-TKIs including AZD9291, CO1686 and brigatinib have showed striking efficacy overcoming acquired resistance driven by T790M secondary mutations. Other novel third-generation EGFR-TKIs such as ASP8274, EGF816, PF-06747775 and avitinib are also being investigated in early-stage clinical trials and the survival and safety data will be released in the near future. Another promising novel EGFR-TKI, namely AZD3759 has showed promising response in patients with brain metastases and leptomeningeal disease. Recently, EAI045, an EGFR allosteric inhibitor, in combination with cetuxmab exhibit antitumor activity in mouse models of lung cancer driven by L858R/T790M/C797S, a resistant mutation of AZD9291. Meanwhile, second-generation ALK inhibitors (ceritinib and alectinib) have entered clinical applications for NSCLC patients with ALK rearrangements after failure of crizotinib and third-generation ALK inhibitors (lorlatinib and ASP3026) are also being evaluated in clinical trials overcoming known ALK resistant mutations. On the other hand, with the development of high-throughput sequencing, called next-generation sequencing (NGS) and genomic technologies, more novel molecular targets such as MET 14 exon skipping splicing mutations have been identified as potential therapeutic targets and simultaneously analyzing hundreds of molecular alterations have turned out reality with limited tumor tissues. In the recent years, the emergence of numbers of oncogenic drivers other than EGFR mutations and ALK rearrangements has divided NSCLC into multiple distinct subtypes amenable to corresponding targeted therapy. For instance, dabrafenib either as monotherapy or in combination with MEK inhibitor (trametinib) has displayed promising antitumor activity and manageable safety profile in patients with BRAF V600E mutations, accounting for around 1.4% of patients with NSCLC. Other novel molecular targets maybe serving as oncogenic drivers including mutations in HER2 (neratinib and pyrotinib) and PI3KCA (BKM120 and GDC0941), ROS1 (entrectinib, foretinib and lorlatinib), RET (XL184) and NTRK (entrectinib) rearrangements and FGFR1 gene amplification (AZD4547, Lenvatinib and FP-1039) are being evaluated either in preclinical settings or early-stage clinical trials. Section not applicable Section not applicable Section not applicable

Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects

Role of NEK2 in tumorigenesis and tumor progression

Targeting NEK2 as a promising therapeutic approach for cancer treatment

High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR

Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.

Nek2 As A Prognostic Marker and Therapeutic Target in Adenocarcinoma of the Lung.

Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma

Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells

One Shoot, Three Birds: Targeting NEK2 Orchestrates Chemoradiotherapy, Targeted Therapy, and Immunotherapy in Cancer Treatment.

The NEK family of serine/threonine kinases as a biomarker for cancer

Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer

Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis

NEK2 promotes the migration, invasion, proliferation of ESCC and mediates ESCC immunotherapy

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer

NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer.

Comprehensive proteomics analysis reveals novel Nek2-regulated pathways and therapeutic targets in cancer

NIMA-related kinase 2 overexpression is associated with poor survival in cancer patients: a systematic review and meta-analysis

PUB007 Novel TKIs in Non-Small Cell Lung Cancer

NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes

NEK2 Induces Drug Resistance Mainly Through Activation of Efflux Drug Pumps and is Associated with Poor Prognosis in Myeloma and Other Cancers.